Aspirin supplemented with quercetin was reported to enhance the therapeutic effects of aspirin in a rat model of preeclampsia. In this study, the underlying mechanisms were further explored. Preeclampsia was induced by L-NAME (50 mg/kg/day) via oral gavage from gestation day (GD)14 to GD19. Aspirin (1.5 mg/kg/day) administration was performed using aspirin mixed with rodent dough from GD0 to GD19. The administration of quercetin (2 mg/kg/day) was performed by intraperitoneal infusion from GD0 to GD19. Protein levels were evaluated using ELISA or Western blot, and microRNA (miRNA) level was evaluated by RT-PCR. Aspirin supplemented with quercetin ameliorated the increase of systolic blood pressure (SBP), proteinuria, tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels, and improved the pregnancy outcomes in preeclampsia rats. Aspirin supplemented with quercetin inhibited miR-155 expression in preeclampsia rats. The decreased miR-155 level in placenta further increased the protein level of SOCS1 and inhibited the phosphorylation of p65. In this study, we demonstrated that aspirin supplemented with quercetin enhanced the effects of aspirin for the treatment of preeclampsia.

Department of Pharmacy Cangzhou Central Hospital Cangzhou Hebei China; Obstetrics Ward 1 Cangzhou Central Hospital Cangzhou Hebei China

See more in PubMed

Shen M, Smith GN, Rodger M, White RR, Walker MC, Wen SW. Comparison of risk factors and outcomes of gestational hypertension and pre-eclampsia. PLoS One. 2017;12:e0175914. doi: 10.1371/journal.pone.0175914. PubMed DOI PMC

Hooijschuur MCE, Ghossein-Doha C, Kroon AA, De Leeuw PW, Zandbergen AAM, Van Kuijk SMJ, Spaanderman MEA. Metabolic syndrome and pre-eclampsia. Ultrasound Obstet Gynecol. 2019;54:64–71. doi: 10.1002/uog.20126. PubMed DOI

Jeyabalan A. Epidemiology of preeclampsia: impact of obesity. Nutr Rev. 2013;71(Suppl 1):S18–S25. doi: 10.1111/nure.12055. PubMed DOI PMC

Yang Y, Le Ray I, Zhu J, Zhang J, Hua J, Reilly M. Preeclampsia Prevalence, Risk Factors, and Pregnancy Outcomes in Sweden and China. JAMA Netw Open. 2021;4:e218401. doi: 10.1001/jamanetworkopen.2021.8401. PubMed DOI PMC

Ramos JGL, Sass N, Costa SHM. Preeclampsia. Rev Bras Ginecol Obstet. 2017;39:496–512. doi: 10.1055/s-0037-1604471. PubMed DOI PMC

Shen H, Zhao X, Li J, Chen Y, Liu Y, Wang Y, Liu X, Cheng W. Severe early-onset PE with or without FGR in Chinese women. Placenta. 2020;101:108–114. doi: 10.1016/j.placenta.2020.09.009. PubMed DOI

van Esch JJA, van Heijst AF, de Haan AFJ, van der Heijden OWH. Early-onset preeclampsia is associated with perinatal mortality and severe neonatal morbidity. J Matern Fetal Neonatal Med. 2017;30:2789–2794. doi: 10.1080/14767058.2016.1263295. PubMed DOI

Atallah A, Lecarpentier E, Goffinet F, Doret-Dion M, Gaucherand P, Tsatsaris V. Aspirin for Prevention of Preeclampsia. Drugs. 2017;77:1819–1831. doi: 10.1007/s40265-017-0823-0. PubMed DOI PMC

Fontana P, Zufferey A, Daali Y, Reny JL. Antiplatelet therapy: targeting the TxA2 pathway. J Cardiovasc Transl Res. 2014;7:29–38. doi: 10.1007/s12265-013-9529-1. PubMed DOI

Cavalca V, Rocca B, Squellerio I, Dragani A, Veglia F, Pagliaccia F, Porro B, et al. In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia. Thromb Haemost. 2014;112:118–127. doi: 10.1160/TH13-10-0844. PubMed DOI

Sakata C, Kawasaki T, Kato Y, Abe M, Suzuki K, Ohmiya M, Funatsu T, et al. ASP6537, a novel highly selective cyclooxygenase-1 inhibitor, exerts potent antithrombotic effect without “aspirin dilemma”. Thromb Res. 2013;132:56–62. doi: 10.1016/j.thromres.2013.03.005. PubMed DOI

Li Q, Yin L, Si Y, Zhang C, Meng Y, Yang W. The bioflavonoid quercetin improves pathophysiology in a rat model of preeclampsia. Biomed Pharmacother. 2020;127:110122. doi: 10.1016/j.biopha.2020.110122. PubMed DOI

Yang S, Song L, Shi X, Zhao N, Ma Y. Ameliorative effects of pre-eclampsia by quercetin supplement to aspirin in a rat model induced by L-NAME. Biomed Pharmacother. 2019;116:108969. doi: 10.1016/j.biopha.2019.108969. PubMed DOI

Bokslag A, van Weissenbruch M, Mol BW, de Groot CJ. Preeclampsia; short and long-term consequences for mother and neonate. Early Hum Dev. 2016;102:47–50. doi: 10.1016/j.earlhumdev.2016.09.007. PubMed DOI

Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: Pathophysiology, Challenges, and Perspectives. Circ Res. 2019;124:1094–1112. doi: 10.1161/CIRCRESAHA.118.313276. PubMed DOI

Shamshirsaz AA, Paidas M, Krikun G. Preeclampsia, hypoxia, thrombosis, and inflammation. J Pregnancy. 2012;2012:374047. doi: 10.1155/2012/374047. PubMed DOI PMC

Knight M, Duley L, Henderson-Smart DJ, King JF. Antiplatelet agents for preventing and treating pre-eclampsia. Cochrane Database Syst Rev. 2000;(2):CD000492. doi: 10.1002/14651858.CD000492. PubMed DOI

Coomarasamy A, Honest H, Papaioannou S, Gee H, Khan KS. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol. 2003;101:1319–1332. doi: 10.1097/00006250-200306000-00030. PubMed DOI

Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2019;2019:CD004659. doi: 10.1002/14651858.CD004659.pub3. PubMed DOI PMC

UstUn Y, Engin-UstUn Y, Ozkaplan E, Otlu B, Sait TekerekoGlu M. Association of Helicobacter pylori infection with systemic inflammation in preeclampsia. J Matern Fetal Neonatal Med. 2010;23:311–314. doi: 10.3109/1476705090312145621. PubMed DOI

Szarka A, Rigo J, Jr, Lazar L, Beko G, Molvarec A. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol. 2010;11:59. doi: 10.1186/1471-2172-11-59. PubMed DOI PMC

Bors W, Michel C, Saran M. Flavonoid antioxidants: rate constants for reactions with oxygen radicals. Methods Enzymol. 1994;234:420–429. doi: 10.1016/0076-6879(94)34112-5. PubMed DOI

Kleemann R, Verschuren L, Morrison M, Zadelaar S, van Erk MJ, Wielinga PY, Kooistra T. Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis. 2011;218:44–52. doi: 10.1016/j.atherosclerosis.2011.04.023. PubMed DOI

Morales-Prieto DM, Ospina-Prieto S, Chaiwangyen W, Schoenleben M, Markert UR. Pregnancy-associated miRNA-clusters. J Reprod Immunol. 2013;97:51–61. doi: 10.1016/j.jri.2012.11.001. PubMed DOI

Karin-Kujundzic V, Sola IM, Predavec N, Potkonjak A, Somen E, Mioc P, Serman A, et al. Novel Epigenetic Biomarkers in Pregnancy-Related Disorders and Cancers. Cells. 2019;8:1459. doi: 10.3390/cells8111459. PubMed DOI PMC

Lv Y, Lu C, Ji X, Miao Z, Long W, Ding H, Lv M. Roles of microRNAs in preeclampsia. J Cell Physiol. 2019;234:1052–1061. doi: 10.1002/jcp.27291. PubMed DOI

Pineles BL, Romero R, Montenegro D, Tarca AL, Han YM, Kim YM, Draghici S, et al. Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol. 2007;196:261e1–e6. doi: 10.1016/j.ajog.2007.01.008. PubMed DOI

Zhang Y, Diao Z, Su L, Sun H, Li R, Cui H, Hu Y. MicroRNA-155 contributes to preeclampsia by down-regulating CYR61. Am J Obstet Gynecol. 2010;202:466e1–e7. doi: 10.1016/j.ajog.2010.01.057. PubMed DOI

Jiang K, Yang J, Guo S, Zhao G, Wu H, Deng G. Peripheral Circulating Exosome-Mediated Delivery of miR-155 as a Novel Mechanism for Acute Lung Inflammation. Mol Ther. 2019;27:1758–1771. doi: 10.1016/j.ymthe.2019.07.003. PubMed DOI PMC